5-MeO-DMT

1. 2026-10-19issueIssued emergency
2. 2026-10-19issueIssued info_card
3. 2026-10-19issueIssued notice
4. 2026-09-27runbrief run
5. 2026-09-27revisionr1.a1
6. 2026-09-24srcHarnessing Pharmacogenomics in Clinical Research on Psychedelic-Assisted Therapy
7. 2026-09-24srcA single inhalation of vapor from dried toad secretion containing 5-MeO-DMT in a naturalistic setting is related to sustained enhancement of satisfaction with life, mindfulness-related capacities, and a decrement of psychopathological symptoms
8. 2026-09-24srcProspective examination of synthetic 5-methoxy-N,N-dimethyltryptamine inhalation: effects on salivary IL-6, cortisol levels, affect, and non-judgment
9. 2026-09-24srcIntranasal 5-MeO-DMT Concomitant with SSRI for Treatment-Resistant Depression: A Proof-of-Concept Trial
10. 2026-09-24srcEffects of monoamine oxidase inhibitor and cytochrome P450 2D6 status on 5-methoxy-N,N-dimethyltryptamine metabolism and pharmacokinetics
11. 2026-09-24srcSerotonergic Psychedelics: A Comparative Review of Efficacy, Safety, Pharmacokinetics, and Binding Profile
12. 2026-09-24srcInteraction of psychedelic tryptamine derivatives with a lipid bilayer
13. 2026-09-24srcTolerance and Cross-Tolerance among Psychedelic and Nonpsychedelic 5-HT2A Receptor Agonists in Mice
14. 2026-09-24srcSerotonin 1A Receptors Modulate Serotonin 2A Receptor-Mediated Behavioral Effects of 5-Methoxy-N,N-dimethyltryptamine Analogs in Mice
15. 2026-09-24srcSynthesis and Characterization of 5-MeO-DMT Succinate for Clinical Use
16. 2026-09-24srcStructure-activity relationships of serotonergic 5-MeO-DMT derivatives: insights into psychoactive and thermoregulatory properties
17. 2026-09-24srcThe clinical pharmacology and potential therapeutic applications of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT)
18. 2026-09-24srcNonlinear pharmacokinetics of 5-methoxy-N,N-dimethyltryptamine in mice
19. 2026-09-24srcPharmacokinetic interactions between monoamine oxidase A inhibitor harmaline and 5-methoxy-N,N-dimethyltryptamine, and the impact of CYP2D6 status
20. 2026-09-24srcPsychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors
21. 2026-09-24srcBenefits and Challenges of Ultra-Fast, Short-Acting Psychedelics in the Treatment of Depression
22. 2026-09-24srcThe epidemiology of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption
23. 2026-09-24srcA narrative synthesis of research with 5-MeO-DMT
24. 2026-09-24srcDrug-drug interactions involving classic psychedelics: A systematic review
25. 2026-09-24srcPhase 1, placebo-controlled, single ascending dose trial to evaluate the safety, pharmacokinetics and effect on altered states of consciousness of intranasal BPL-003 (5-methoxy-N,N-dimethyltryptamine benzoate) in healthy participants
26. 2026-09-24srcIndolealkylamines: biotransformations and potential drug-drug interactions
27. 2026-09-24srcPsychedelics and the human receptorome
28. 2026-09-24srcRecreational use, analysis and toxicity of tryptamines.
29. 2026-09-24srcIntensity of Mystical Experiences Occasioned by 5-MeO-DMT and Comparison With a Prior Psilocybin Study
30. 2026-09-24srcA phase 1/2 trial to assess safety and efficacy of a vaporized 5-methoxy-N,N-dimethyltryptamine formulation (GH001) in patients with treatment-resistant depression
31. 2026-09-24src5-MeO-DMT for post-traumatic stress disorder: a real-world longitudinal case study
32. 2026-09-24srcStructural Pharmacology of Bufotenine Derivatives in Activating the 5-HT1A Receptor for Therapeutic Potential in Depression and Anxiety
33. 2026-09-24srcScreening for endogenous substrates reveals that CYP2D6 is a 5-methoxyindolethylamine O-demethylase
34. 2026-09-24srcPsychedelic 5-methoxy-N,N-dimethyltryptamine: metabolism, pharmacokinetics, drug interactions, and pharmacological actions
35. 2026-09-24srcSchedules of controlled substances: placement of 5-methoxy-N,N-dimethyltryptamine into Schedule I of the Controlled Substances Act. Final rule.
36. 2026-09-24srcPotentiation of 5-methoxy-N,N-dimethyltryptamine-induced hyperthermia by harmaline and the involvement of activation of 5-HT1A and 5-HT2A receptors
37. 2026-09-24srcThe excitability and rhythm of medullary respiratory neurons in the cat are altered by the serotonin receptor agonist 5-methoxy-N,N-dimethyltryptamine
38. 2026-09-24srcBufo alvarius: a potent hallucinogen of animal origin
39. 2026-09-24srcGH Research Phase 2b Trial Results: GH001 in Treatment-Resistant Depression
40. 2026-09-24src5-MeO-DMT synthesis history and physical properties
41. 2026-09-24srcIUPHAR/BPS Guide to Pharmacology — 5-MeO-DMT Ligand Activity
42. 2026-09-24srcLegal status of 5-MeO-DMT by jurisdiction
43. 2026-09-24srcUsona Institute NCT05698095: IM 5-MeO-DMT Phase 1 PK Study
44. 2026-09-24srcInhaled 5-methoxy-N,N-dimethyltryptamine: Supportive context associated with positive acute and enduring effects
45. 2026-09-04issueIssued emergency
46. 2026-09-04issueIssued info_card
47. 2026-09-04issueIssued notice
48. 2026-06-04proposal41 value proposals approved togetherone review action inferred from a shared reviewer and instant — the graph records one activity per proposal
49. 2026-06-04publicationPublication — backfill
50. 2026-04-24revisionRevision 1
51. 2026-04-24genGeneration — pipeline-v5pipeline-v5
52. 2026-04-24rungeneration run

The same entries, as forms: six forms.